Back to: Psychedelics, Entheogens, and Consciousness Expansion
Navigating the Regulatory Landscape
A Comparative Profile of Esketamine, MDMA, and Psilocybin
Picture three medicine cabinets, side by side. In the first, a nasal spray that reached the pharmacy in 2019 and needed only six years to shed its supervision requirement entirely. In the second, an empty shelf where a PTSD treatment should be sitting right now, three years after its Phase 3 data came in strong enough to make headlines on its own. In the third, a bottle that does not exist yet, but that a sitting president ordered the FDA to review in a matter of weeks rather than the better part of a year.
Same federal agency. Same basic legal standard. Three wildly different outcomes. If you have already read the companion piece to this module, you know why: two clocks are running underneath every one of these stories, and they very rarely tell the same time.
The Two Clocks, Applied Three Times
I called them the Evidence Clock and the Readiness Clock in the last reading, and I am going to keep using that language here, because once you can see the two clocks, you cannot really unsee them. The Evidence Clock ticks forward one clinical trial at a time. It is slow, it is careful, and it genuinely does not care what is happening in Washington. The Readiness Clock is a different animal entirely. It measures how comfortable an institution has become with a class of compounds, how much political will exists to move a file forward, and how much the agency’s own credibility is on the line with every decision it signs.
What this piece does differently is put three compounds on the table at once, esketamine, MDMA, and psilocybin, with methylone riding along for the comparison, so you can watch both clocks run at different speeds across all three stories simultaneously. Read that way, the differences stop looking random and start looking like a pattern you can use.
Esketamine: The Compound That Never Had to Fight
Esketamine is the quiet case in this comparison, and that quietness is exactly what makes it instructive. In 2019, the FDA approved it, sold under the brand name Spravato, for treatment resistant depression, though only as an add-on to an oral antidepressant and only under strict in-office monitoring. By January of 2025, the agency had gone further, clearing esketamine for standalone use, no companion antidepressant required, making it the first monotherapy of its kind for treatment resistant depression.
Six years from first approval to full independence is not nothing but set it beside where MDMA and psilocybin sit right now, and esketamine looks like it found an express lane.
Here is why. Esketamine is an NMDA receptor antagonist. Chemically and pharmacologically, that puts it in the same family as ketamine, a drug anesthesiologists and emergency physicians have been using safely and routinely since the 1970s. Its dissociative effects, feeling detached from your body or your surroundings, are documented in a clinical literature that predates the current psychedelic renaissance by decades. When esketamine’s developers walked into the FDA, they were not asking regulators to trust an unfamiliar class of drug. They were asking regulators to extend trust they had already extended, to a new indication.
That is the Readiness Clock, and it was already most of the way around the dial before the first depression trial ever started. Esketamine’s story is not about superior data. Its Phase 3 results were solid but unremarkable by the standards this field would later set. What moved fast was institutional comfort, the sense among regulators that they already understood the pharmacological neighborhood this drug lived in.
The lesson for a reader working through the MDMA and psilocybin stories that follow: do not assume every compound is starting the readiness race from the same position. Some inherit decades of goodwill they never had to earn themselves.
MDMA: When the Evidence Clock Outran the Institution
If esketamine shows what happens when the Readiness Clock is already warmed up, MDMA shows what happens when it is not, no matter how loud the Evidence Clock gets.
Start with the numbers, because they deserve to be taken seriously before we get to why they were not enough. Six Phase 2 trials, run by the Multidisciplinary Association for Psychedelic Studies between 2004 and 2017, found that fifty four percent of participants receiving full dose MDMA assisted therapy no longer met diagnostic criteria for PTSD after two sessions. The Phase 3 trials that followed pushed that figure higher still: sixty-seven to seventy one percent of participants in remission by the end of treatment. In a field where a modest antidepressant response is often measured in single digit improvements, those are not small numbers.
And in August of 2024, after an FDA advisory committee had already voted nine to two against recommending approval, the agency issued a formal rejection, a Complete Response Letter. For a treatment with that kind of efficacy data, the outcome surprised a lot of people who had been watching only the Evidence Clock.
The CRL itself stayed out of public view for more than a year. When the FDA finally released the full document in September of 2025, the reasoning it laid out had almost nothing to do with whether MDMA relieves PTSD symptoms and everything to do with whether the trial could be trusted to prove it. Close to forty percent of participants had prior experience with MDMA, meaning many of them could likely guess which arm of the trial they had been assigned to, which is close to fatal for a study that depends on genuine blinding. There were adverse events, including euphoric responses relevant to assessing abuse potential, that went unreported. Investigators had documented at least one case of therapist misconduct during a Phase 2 session. And the long-term data needed to answer basic questions, how long the benefit lasts, what retreatment should look like, simply was not there yet.
The fallout arrived fast and it arrived hard. Within days of the rejection, in August of 2024, the journal Psychopharmacology retracted three MAPS linked studies over an undisclosed conflict of interest tied to the same misconduct allegation the FDA had flagged. By late that same year, Lykos Therapeutics, the MAPS affiliated public benefit corporation that had carried the MDMA program through Phase 3, had cut roughly three quarters of its staff.
None of that erased the fifty four percent, or the sixty-seven to seventy one percent. What it confirmed, in about as concrete a way as this field ever offers, is that efficacy and trial integrity are two different tests, and a compound must pass both. The Evidence Clock said MDMA worked. The Readiness Clock said the institution could not yet trust the story being told about how well it worked, or by whom. Both of those statements were true at the same time, which is precisely the kind of double truth this module keeps asking you to hold onto instead of collapsing into one side or the other.
Psilocybin and Methylone: The Readiness Clock’s Sudden Sprint
By early 2026, something shifted, and it was not the underlying science.
On April 18, 2026, the President signed an executive order directing federal agencies to accelerate research, review, and approval of psychedelic drugs for serious mental health conditions that have not responded to standard treatment. Six days later, on April 24, the FDA acted on it, issuing National Priority Vouchers, a mechanism that compresses the standard ten to twelve month drug application review down to something closer to one or two months, to three programs: Compass Pathways, for its synthetic psilocybin formulation COMP360, aimed at treatment resistant depression; the Usona Institute, for psilocybin targeting major depressive disorder more broadly; and Transcend Therapeutics, for methylone, an MDMA related but chemically distinct compound, aimed at PTSD.
Worth a footnote here, because the regulatory landscape keeps moving even while you are reading about it: in late March of 2026, just weeks before that voucher was issued, the pharmaceutical company Otsuka announced it was acquiring Transcend Therapeutics outright, in a deal worth roughly one point two billion dollars, specifically to carry the methylone program, internally designated TSND-201, through to approval. By the time you read this, the compound that started as a small biotech’s bet on learning from MDMA’s mistakes may be moving forward under a much larger company’s name. The science did not change. The Readiness Clock, in the form of who has the resources to finish the job, kept turning anyway.
Compass Pathways is the furthest along of the three, and its data is genuinely worth sitting with. In June of 2025, the company reported the first positive Phase 3 result for any classic psychedelic in United States history: a single twenty-five milligram dose of COMP360 produced a statistically significant reduction in depression severity at week six. A second Phase 3 trial, COMP006, reported its own topline results in February of 2026, and here the numbers deserve some precision, because it is easy to round them into something they are not. Thirty nine percent of participants in the twenty-five milligram arm achieved what the trial defined as a clinically meaningful response, a MADRS score reduction of twenty five percent or more, by week six. That is a response rate, not a remission rate, and the two words are worth keeping distinct.
Follow up data released in July of 2026 showed that response holding, on average, through week twenty-six, and showed something further: of the participants who had responded but had not yet reached full remission by week six, nearly thirty percent went on to achieve remission after a second dose. That is real and it is encouraging, but it is a subgroup finding layered inside a response rate, not a flat thirty percent of everyone who walked in the door. Precision matters here, because this is exactly the kind of statistic that gets flattened into a soundbite on its way from a press release to a headline, and a soundbite is not evidence.
Compass has already filed its New Drug Application, with an FDA decision possible by late 2026 or into 2027.
It would be easy, reading all of this, to conclude that science has arrived and the rest is paperwork. That would be the acceleration error, and it is worth naming directly. FDA Commissioner Marty Makary has been explicit that expedited review timelines do not mean a lowered evidentiary bar. As he put it, the agency’s development standards have to stay grounded in sound science and rigorous clinical evidence.
“If they do get approved, these are not the medications you’ll just pick up at a pharmacy. These are given in a controlled, supervised setting in a hospital.” – FDA Commissioner Marty Makary
Then there is methylone, which deserves attention for a different reason. It is a case study in what it looks like to take a regulatory rejection seriously as information rather than as a verdict. The methylone trial was not built to resubmit MDMA’s story and hope for a friendlier reading. Methylone is chemically distinct from MDMA, which helps address the blinding problem that sank the earlier trial, and the protocol was shaped directly around the FDA’s stated objections: tighter screening for participants’ prior drug experience, more rigorous adverse event reporting, and a clearer plan for measuring how long benefits actually last. Whether that redesign succeeds is still an open question. The program remains in Phase 3 as of this writing, making it the least mature of the three vouchered programs. But the instinct behind it, treat the setback as a list of what still needs proving rather than as a door closing, is worth remembering the next time you hit a wall in your own work, inside this field or anywhere else.
Reading the Comparison Honestly
Line the three stories up and a pattern emerges that has nothing to do with which drug is best and everything to do with which clock was running fastest when it mattered.
Esketamine moved quickly because the Readiness Clock had a head start it never had to build from scratch. MDMA had a fast Evidence Clock and a stalled Readiness Clock, and the stall won. Psilocybin and methylone are riding a Readiness Clock that just found a burst of political and administrative energy, while their own Evidence Clocks continue ticking at the same careful pace they always have.
I would ask you to resist two temptations here, because I have watched both trip up otherwise careful readers. The first is treating MDMA’s 2024 rejection as proof the whole field was cynically overhyped from the start. It was not. The underlying trial data was some of the strongest psychiatry has produced in a generation, and methylone’s redesigned trial exists specifically because that data pointed toward a real effect worth pursuing more carefully. The second temptation runs the opposite direction: treating 2026’s vouchers and executive orders as proof the science is now fully settled. It is not. Commissioner Makary’s own words rule that reading out. Procedural speed and scientific certainty are not the same thing and conflating them is how a genuinely promising field ends up either dismissed too early or oversold too soon.
What has not changed, through any of this, is the actual bar. The FDA still requires substantial evidence of safety and efficacy before it approves anything, psychedelic or otherwise. What changed in 2026 was how quickly a completed application gets read once it clears that bar, not the height of the bar itself.
Questions Worth Asking of Any Regulatory Headline
When you next see a headline claiming a psychedelic treatment failed, or succeeded, I would offer four questions worth running it through before you decide what it actually means.
First, has the compound shown statistically significant safety and efficacy across more than one Phase 3 trial, not just a single promising result. Second, has the trial design addressed the blinding and selection bias problems that sank MDMA’s first attempt, rather than simply repeating the same structure and hoping for a better outcome. Third, is the delivery model built around supervised administration in a clinical setting, which is the standard the FDA has held to consistently, rather than implying eventual take home use that no agency official has promised. And fourth, does the path forward account for the steps that sit beyond FDA approval itself, DEA rescheduling chief among them, since these compounds remain Schedule I substances until that separate process runs its course.
None of these four questions will tell you whether a treatment works. The trial data does that. What they will tell you is whether a given announcement, a voucher, an executive order, a topline press release, is evidence of clinical progress or evidence of administrative momentum. Increasingly, in this field, you need to be able to tell the two apart.
At a Glance: Four Compounds, Four Positions on the Dial
A quick reference for where each compound stood as of August 2026, and the single lesson its regulatory story teaches best.
| Compound | Regulatory Status (Aug. 2026) | Pharmacological Class | What Its Story Teaches |
| Esketamine (Spravato) | Approved 2019 as an add-on; expanded to standalone monotherapy in January 2025 | NMDA receptor antagonist (dissociative) | Institutional familiarity can move the Readiness Clock even when the Evidence Clock is unremarkable |
| MDMA-assisted therapy (Lykos) | Complete Response Letter issued August 2024; letter made public September 2025; not currently approved | Entactogen; serotonin, dopamine, and norepinephrine releasing agent | Strong efficacy data cannot substitute for trial integrity and durable safety data |
| Psilocybin, COMP360 (Compass Pathways) | National Priority Voucher issued April 2026; NDA filed; decision possible late 2026 or 2027 | Classic psychedelic; serotonin 5-HT2A receptor agonist | Positive Phase 3 data plus favorable political timing compress the review clock, not the evidentiary bar |
| Psilocybin (Usona Institute) | National Priority Voucher issued April 2026, targeting major depressive disorder | Classic psychedelic; serotonin 5-HT2A receptor agonist | Institutional readiness can extend to an entire compound class, not just one company’s molecule |
| Methylone, TSND-201 (Otsuka, formerly Transcend) | Phase 3 in progress; National Priority Voucher issued April 2026 | MDMA-related entactogen, chemically distinct from MDMA | A trial can be redesigned specifically to answer a prior rejection’s stated objections |
Two Clocks, Three Stories, One Discipline
None of these four compounds is going to resolve itself into a simple headline anytime soon, and if this piece has done its job, you no longer expect one to. What I hope you carry forward from esketamine’s quiet ascent, MDMA’s hard rejection, and psilocybin’s sudden acceleration is the same discipline the last reading asked of you: before you decide what a piece of regulatory news means, ask which clock it is actually reporting on.
I have spent enough years watching institutions, in engineering, in the Navy, in life generally, to trust this much: the compounds that eventually reach patients will be the ones where both clocks finally agree, not the ones where one clock got loud enough to drown out the other. That agreement is still being negotiated, trial by trial, letter by letter, for MDMA and psilocybin alike. Esketamine already found it. The rest of the field is still finding its way there, in real time, while you and I are reading about it.
Stay with both clocks. It is the only way to read this field honestly.
Selected Sources
NPR, “FDA allows standalone use of nasal spray antidepressant Spravato (esketamine),” January 21, 2025.
Johnson & Johnson, “SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression,” press release, January 2025.
MAPS, “Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy,” September 4, 2025.
STAT News, “FDA criticism of MDMA-assisted therapy is an opportunity for psychedelic medicine,” October 30, 2025.
Fierce Biotech, “In a one-two punch for Lykos, 3 articles on MDMA treatment retracted due to unethical conduct,” August 2024.
The White House, “Fact Sheet: President Donald J. Trump is Accelerating Medical Treatments for Serious Mental Illness,” April 18, 2026.
CNN, “FDA moves to fast-track review of psilocybin and methylone for mental health,” April 24, 2026.
Compass Pathways, investor press releases on COMP005 (June 2025), COMP006 (February 17, 2026), and six-month COMP006 follow-up data (July 7, 2026).
Otsuka Pharmaceutical, “Otsuka Pharmaceutical to Acquire Transcend Therapeutics,” news release, March 27, 2026.
Psychedelic Alpha, “Breaking: FDA Awards Priority Review Vouchers to Otsuka, Compass, and Usona,” April 2026.